AndersonRPClarkDA. Amphotericin B toxicity reduced by administration in fat emulsion. Ann Pharmacother1995; 29: 496–500.
2.
LeakeHAAppleyardMNHartleyJPR. Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B. J Infect1994; 28: 319–22.
3.
MacedoMCMADulleyFLOstronoffMMachadoCMZambonEMatsumotoCEffectiveness of amphotericin B in lipid emulsion for treating fungal septicemia in granulocytopenic patients (letter). Clin Infect Dis1994; 19: 366–7.
4.
ChavanetPYGarryICharlierNCaillotDKistermanJPD'AthisMTrial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ1992; 305: 921–5.
5.
MoreauPMilpiedNFayetteNRameeJFHarousseauJL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother1992; 30: 535–41.
6.
CalliotDChavanetPCasasnovasOSolaryEZanettaGBuissonMClinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur J Clin Microbiol Infect Dis1992; 11: 722–5.
7.
PascualBAyestaranAMontoroJBOliverasJEstibalezAJuliaAAdministration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann Pharmacother1995; 29: 1197–201.
8.
ThakurCP. Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar. Trans R Soc Trop Med Hyg1994; 88: 698–9.
9.
CaillotDRenyGSolaryECasasnovasOChavanetPBonnotteBA controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother1994; 33: 603–13.
10.
TrisselLA. Amphotericin B does not mix with fat emulsion (letter). Am J Health-Syst Pharm1995; 52: 1463–4.
